June 9, 2022 C-Path Launches Unique Translational Therapeutics Accelerator with Support from Cottrell Foundation The global accelerator will transform academic discoveries to drug development opportunities TUCSON, Ariz., June 9, 2022 — Criti
June 8, 2022 PRO Consortium Announces Publication of Open Access Article C-Path’s PRO Consortium is pleased to announce that “Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ)
June 8, 2022 Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ): measurement properties and estimated clinically meaningful thresholds from a phase 3 study
June 7, 2022 C-Path and MitoAction Announce Data Sharing Agreement to Support Treatment Development in Mitochondrial Disease TUCSON, Ariz., June 7, 2022 — Critical Path Institute (C-Path) and MitoAction today announced a joint collaboration to incorpora
June 2, 2022 xCures joins C-Path’s Cure Drug Repurposing Collaboratory to Deliver AI-enabled Data Abstraction of Health Records Members of CDRC will be able to utilize xCures’ technology to quickly abstract and structure clinical data to support drug repur
June 2, 2022 Biochemist, Biotechnology Expert to Lead C-Path’s Type 1 Diabetes Consortium TUCSON, Ariz., June 2, 2022 — Critical Path Institute (C-Path) has named Elnaz Atabakhsh, Ph.D., as Executive Director of its Ty
June 1, 2022 C-Path Receives Largest Data Transfer to Date from UK’s National Neonatal Research Database The EPR data transfer is the first from the United Kingdom and includes data from nearly 200 hospitals TUCSON, Ariz., June
May 31, 2022 FSHD Society and Critical Path Institute Collaborate to Collect Clinical Trial Data TUCSON, Ariz., May 23, 2022 — The FSHD Society, a research-focused patient advocacy nonprofit dedicated to bringing treatments
May 23, 2022-February 8, 2024 View Now | International 2022 Drug-induced Kidney Injury Biomarker Workshop On May 23-24, 2022, the Critical Path Institute hosted the International Drug-induced Kidney Injury Biomarker Workshop. In collabo